The U.S. Food and Drug Administration on Sept. 21 approved Incyte Corp.’s cream Opzelura for treating the inflammatory skin condition atopic dermatitis, commonly called eczema, in adolescents and adults with boxed warnings.
Sanofi raised the company’s 2021 profit forecast on July 29 after its vaccines and star eczema treatment Dupixent helped the French drugmaker beat second-quarter results expectations.
Sanofi and Regeneron’s Dupixent product won approval from the European Commission to treat children aged 6-11 years suffering from severe atopic dermatitis, often known as eczema.
Regeneron Pharmaceuticals will repurchase about $5 billion of the U.S. drugmaker’s shares directly from France’s Sanofi, without altering their 17-year partnership.
The U.S. Food and Drug Administration regulatory body accepted for priority review the use of Sanofi and Regeneron’s Dupixent product for children aged 6-11 with moderate-to-severe eczema,
Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.
Paris-based Sanofi announced the inaugural opening of the company’s first new digital manufacturing facility for biologics production in Framingham, Massachusetts.
The U.S. Food and Drug Administration approved expanded use of Regeneron Pharmaceuticals Inc. and Sanofi SA’s eczema drug Dupixent to include patients aged between 12 and 17 years.
Sanofi will pay Regeneron about $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body’s own immune system fight cancer.
Drugmakers Sanofi and Regeneron received positive results for Dupixent, which treats eczema and is seen as a key driver of future revenues.